Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2010-5-24
pubmed:abstractText
Flavopiridol, a cyclin-dependent kinase inhibitor, is cytotoxic to leukemic blasts. In a Phase II study, flavopiridol 50 mg/m(2) was given by 1-h infusion daily x 3 beginning day 1 followed by 2 g/m(2)/72 h ara-C beginning day 6 and 40 mg/m(2) mitoxantrone on day 9 (FLAM) to 45 adults with newly diagnosed acute myelogenous leukemia (AML) with multiple poor-risk features. Thirty patients (67%) achieved complete remission (CR) and 4 (9%) died. Twelve (40%) received myeloablative allogeneic bone marrow transplant (BMT) in first CR. Median OS and DFS are not reached (67% alive 12.5-31 months, 58% in CR 11.4-30 months), with median follow-up 22 months. Sixteen received FLAM in CR, with median OS and DFS 9 and 13.1 months, and 36% alive at 21-31 months. Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-10699068, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-11431468, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-12393746, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-12429644, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-12531222, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-12538483, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-12702569, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-14673054, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-16322302, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-16432172, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-16455952, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-16553, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-16690529, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-17003373, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-17095617, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-17488990, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-17671131, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-18450602, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-18981292, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-19144991, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-19144992, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-19776405, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-19776406, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-20378170, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-2676014, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-5258033, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-7003298, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-8250970, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-8674031, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-8895733, http://linkedlifedata.com/resource/pubmed/commentcorrection/19962759-9269999
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1873-5835
pubmed:author
pubmed:copyrightInfo
Copyright 2009 Elsevier Ltd. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
34
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
877-82
pubmed:dateRevised
2011-9-26
pubmed:meshHeading
More...